Sociedad Americana de Hirudoterapia

Pharmaceutical Services — Ministry of Health of the Republic of Cyprus

Cyprus PHS · Cyprus · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Cyprus's Pharmaceutical Services (Ministry of Health) — leeches fall under EU medical-device frameworks (MDR 2017/745) as implemented through Cypriot national law; leech-specific national authorisation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Cyprus
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Cypriot Medicines (Use by Man) (Quality, Supply and Prices) Laws 70(I)/2001 et seq., as amended
  • EU Medical Device Regulation (MDR) 2017/745 — as transposed into Cypriot law
  • Cypriot Medical Devices Laws

Prescriber Requirements

  • Cyprus Medical Council–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Pharmaceutical Services registration as applicable; Greek and English-language labelling. Standard cold-chain conditions; EU intra-community movement under MDR applies.

Import/Export Rules

Free movement within the EU single market under MDR; Veterinary Services clearance for live invertebrates from non-EU origin; CITES Appendix II paperwork for Hirudo medicinalis / verbana on extra-EU import.

Reimbursement Context

General Healthcare System (GeSY) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general EU MDR framework as transposed into Cypriot law. Cyprus Pharmaceutical Services coordinates with EMA and other EU NCAs; whether leech-specific guidance exists has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.